The Pharma Data

DECEMBER 3, 2020

Through our partnership with Clover we hope to make hundreds of millions of doses of this vaccine globally accessible through COVAX, if it is proven to be safe and effective.”. Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JANUARY 31, 2021

Through this partnership we hope to make hundreds of millions of doses of this vaccine globally accessible through COVAX, if it is proven to be safe and effective.” Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52